Rules-Based Medicine has launched its OncologyMAP product for the quantitative measurement of 101 cancer-related proteins in serum.
RBM released the platform to a limited number of customers last October and is now making it available worldwide. The test is validated to clinical laboratory standards, which allows protein biomarker discovery research to be more easily translated to clinical trials, the company said.
Plexera this week launched its new PlexArray HT system, a label-free surface plasmon resonance-based protein interaction detection system.
According to the company, the system can analyze thousands of protein interactions in 30 minutes, using high array density sensor chips that come with multiple surface chemistries for protein, nucleic acid, small molecule, and live cell immobilization experiments.